These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28869437)

  • 1. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients.
    Yuan GQ; Wei NL; Mu LY; Wang XQ; Zhang YN; Zhou WN; Pan YW
    Cancer Biomark; 2017 Dec; 20(4):443-452. PubMed ID: 28869437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
    Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
    PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients.
    Sana J; Radova L; Lakomy R; Kren L; Fadrus P; Smrcka M; Besse A; Nekvindova J; Hermanova M; Jancalek R; Svoboda M; Hajduch M; Slampa P; Vyzula R; Slaby O
    Carcinogenesis; 2014 Dec; 35(12):2756-62. PubMed ID: 25322872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 4-miRNA signature predicts the therapeutic outcome of glioblastoma.
    Niyazi M; Pitea A; Mittelbronn M; Steinbach J; Sticht C; Zehentmayr F; Piehlmaier D; Zitzelsberger H; Ganswindt U; Rödel C; Lauber K; Belka C; Unger K
    Oncotarget; 2016 Jul; 7(29):45764-45775. PubMed ID: 27302927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
    Zhao H; Wang S; Song C; Zha Y; Li L
    World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma.
    Khalil S; Fabbri E; Santangelo A; Bezzerri V; Cantù C; Di Gennaro G; Finotti A; Ghimenton C; Eccher A; Dechecchi M; Scarpa A; Hirshman B; Chen C; Ferracin M; Negrini M; Gambari R; Cabrini G
    Oncotarget; 2016 May; 7(19):28195-206. PubMed ID: 27057640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
    Lakomy R; Sana J; Hankeova S; Fadrus P; Kren L; Lzicarova E; Svoboda M; Dolezelova H; Smrcka M; Vyzula R; Michalek J; Hajduch M; Slaby O
    Cancer Sci; 2011 Dec; 102(12):2186-90. PubMed ID: 21895872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
    Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
    Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 4-miRNA signature to predict survival in glioblastomas.
    Hermansen SK; Sørensen MD; Hansen A; Knudsen S; Alvarado AG; Lathia JD; Kristensen BW
    PLoS One; 2017; 12(11):e0188090. PubMed ID: 29136645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long non-coding RNA signature in glioblastoma multiforme predicts survival.
    Zhang XQ; Sun S; Lam KF; Kiang KM; Pu JK; Ho AS; Lui WM; Fung CF; Wong TS; Leung GK
    Neurobiol Dis; 2013 Oct; 58():123-31. PubMed ID: 23726844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.
    Matos B; Bostjancic E; Matjasic A; Popovic M; Glavac D
    Radiol Oncol; 2018 Nov; 52(4):422-432. PubMed ID: 30511935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
    Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
    J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
    Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
    J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.
    Reifenberger G; Hentschel B; Felsberg J; Schackert G; Simon M; Schnell O; Westphal M; Wick W; Pietsch T; Loeffler M; Weller M;
    Int J Cancer; 2012 Sep; 131(6):1342-50. PubMed ID: 22139906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.
    Zhang W; Zhang J; Yan W; You G; Bao Z; Li S; Kang C; Jiang C; You Y; Zhang Y; Chen CC; Song SW; Jiang T
    Cancer; 2013 Feb; 119(4):814-24. PubMed ID: 22990979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.